# A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

> **NCT02264639** · PHASE1 · COMPLETED · sponsor: **Apellis Pharmaceuticals, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** Pegcetacoplan

## Key facts

- **NCT ID:** NCT02264639
- **Lead sponsor:** Apellis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-23
- **Primary completion:** 2018-10-22
- **Final completion:** 2018-10-22
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264639, "A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT02264639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*